Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for vasculoprotection in septic shock with microcirculatory dysfunction
2025-524820-23-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Forxiga with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Planned start Sep 2026; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2025-524820-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524820-23-00.